Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optical Genome Mapping Enhances Structural Variant Detection and Refines Risk Stratification in Chronic Lymphocytic Leukemia.

Genes·2026
Same author

Loss of JAK1 Function Causes G2-M Cell-Cycle Defects Vulnerable to KIF18A Inhibition.

Cancer research·2026
Same author

High glucose enhances lung cancer cell aggressiveness: the impacts of GLUT1, UAP1, UGP2, and N-linked glycosylation.

Glycobiology·2025
Same author

PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity.

bioRxiv : the preprint server for biology·2025
Same author

OST Catalytic Subunit Redundancy Enables Therapeutic Targeting of N-Glycosylation.

bioRxiv : the preprint server for biology·2024
Same author

Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity.

JNCI cancer spectrum·2024

Related Experiment Video

Updated: May 9, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.5K

PLK4 Inhibition as a Strategy to Enhance Non-Small Cell Lung Cancer Radiosensitivity.

Irma G Dominguez-Vigil1, Kishore Banik1, Marta Baro1

  • 1Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut.

Molecular Cancer Therapeutics
|April 29, 2025
PubMed
Summary

Targeting Polo-like kinase 4 (PLK4) with CFI-400945 enhances radiation therapy for non-small cell lung cancer (NSCLC). This approach increases cancer cell death by amplifying centrosomes and disrupting mitosis, improving tumor control.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
00:09

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

6.9K

Related Experiment Videos

Last Updated: May 9, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.5K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
00:09

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

6.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Non-small cell lung cancer (NSCLC) has high mortality, with suboptimal local control after chemoradiation.
  • Polo-like kinase 4 (PLK4) is overexpressed in NSCLC and regulates centrosome duplication and cell cycle.
  • PLK4 inhibition is a potential therapeutic strategy for NSCLC.

Purpose of the Study:

  • To investigate if inhibiting PLK4 with CFI-400945 can radiosensitize NSCLC.
  • To determine the mechanism by which PLK4 inhibition affects radiation response in NSCLC.

Main Methods:

  • NSCLC cell lines and normal lung fibroblasts were treated with CFI-400945 and/or radiation.
  • Cell cycle distribution, centrosome amplification, and cell death were analyzed.
  • Tumor growth delay was assessed in NSCLC xenograft models.

Main Results:

  • CFI-400945 demonstrated radiosensitization of NSCLC cells but not normal fibroblasts.
  • Combination therapy increased G2/M arrest, centrosome amplification, and mitotic catastrophe.
  • CFI-400945 enhanced radiation-induced tumor growth delay in vivo.

Conclusions:

  • Targeting PLK4 with CFI-400945 is a novel strategy to enhance NSCLC radiosensitivity.
  • The mechanism involves potentiation of centrosome amplification and mitotic catastrophe.
  • This approach shows promise for improving NSCLC treatment outcomes.